文献速递血栓与止血

小干扰RNA介导的等位基因特异性抑制突变型血管性血友病因子纠正显性负性多聚化缺陷

Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor.
PubMed 文献 · J Thromb Haemost · 2018-06-01

本研究探讨用小干扰RNA(siRNA)靶向血管性血友病因子(VWF)基因常见单核苷酸多态性(SNP)以实现等位基因特异性抑制。在稳定表达VWF的HEK293细胞中,12条siRNA能有效抑制单个VWF等位基因,11条siRNA共转染时优先抑制靶向等位基因;针对VWD 2A型突变VWF p.Cys2773Ser的siRNA可改善其多聚化模式。作者认为等位基因特异性siRNA有望用于显性负性VWD的治疗。

要点

  • 靶向VWF基因SNP的siRNA可在HEK293细胞中实现等位基因特异性抑制。
  • 11条siRNA共转染时对靶向等位基因的抑制明显优于非靶向等位基因。
  • siRNA可改善VWF p.Cys2773Ser突变所致严重多聚化缺陷。

核心结论

  • 等位基因特异性siRNA能基于单核苷酸差异区分VWF等位基因,并改善VWF p.Cys2773Ser所致的严重多聚化缺陷,作者认为这为显性负性VWD的siRNA治疗带来希望。

研究设计与样本

  • 体外研究:选取VWF内4个预测杂合度高的SNP,针对其两个等位基因设计siRNA,在稳定表达VWF的HEK293细胞中检测siRNA效率、等位基因特异性及表型改善。

主要发现

  • 12条siRNA能在稳定产生VWF的HEK293细胞中有效抑制单个VWF等位基因。
  • 这些siRNA与两个VWF等位基因瞬时共转染时,11条siRNA对靶向等位基因的抑制明显优于非靶向等位基因。
  • siRNA介导改善了VWD 2A型突变VWF p.Cys2773Ser的多聚化模式。

关键数值与推荐

  • 4个预测杂合度高的VWF SNP被选为靶点,针对每个SNP的两个等位基因设计siRNA。
  • 12条siRNA有效抑制单个VWF等位基因,其中11条在共转染时优先抑制靶向等位基因。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Substitution therapy for von Willebrand (VW) disease leaves mutant VW factor (VWF) unhindered. Presence of mutant VWF may negatively affect phenotypes despite treatment. Inhibition of VWF by allele-specific siRNAs targeting single-nucleotide polymorphisms is effective. Allele-specific inhibition of VWF p.Cys2773Ser improves multimerization. SUMMARY: Background Treatment of the bleeding disorder von Willebrand disease (VWD) focuses on increasing von Willebrand factor (VWF) levels by administration of desmopressin or VWF-containing concentrates. Both therapies leave the production of mutant VWF unhindered, which may have additional consequences, such as thrombocytopenia in patients with VWD type 2B, competition between mutant and normal VWF for platelet receptors, and the potential development of intestinal angiodysplasia. Most cases of VWD are caused by dominant-negative mutations in VWF, and we hypothesize that diminishing expression of mutant VWF positively affects VWD phenotypes. Objectives To investigate allele-specific inhibition of VWF by applying small interfering RNAs (siRNAs) targeting common single-nucleotide polymorphisms (SNPs) in VWF. This approach allows allele-specific knockdown irrespective of the mutations causing VWD. Methods Four SNPs with a high predicted heterozygosity within VWF were selected, and siRNAs were designed against both alleles of the four SNPs. siRNA efficiency, allele specificity and siRNA-mediated phenotypic improvements were determined in VWF-expressing HEK293 cells. Results Twelve siRNAs were able to efficiently inhibit single VWF alleles in HEK293 cells that stably produce VWF. Transient cotransfections of these siRNAs with two VWF alleles resulted in a clear preference for the targeted allele over the untargeted allele for 11 siRNAs. We also demonstrated siRNA-mediated phenotypic improvement of the VWF multimerization pattern of the VWD type 2A mutation VWF p.Cys2773Ser. Conclusions Allele-specific siRNAs are able to distinguish VWF alleles on the basis of one nucleotide variation, and are able to improve a severe multimerization defect caused by VWF p.Cys2773Ser. This holds promise for the therapeutic application of allele-specific siRNAs in dominant-negative VWD.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. de Jong A, Dirven RJ, Oud JA, et al. Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor. J Thromb Haemost. 2018. PMID: 29734512. doi:10.1111/jth.14140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。